Drug intelligence / Profile preview

hemostatic matrix + bovine thrombin

Development stage
Unknown
Lead developer
Baxter
Modality
Recombinant Proteins and Enzymes, Device-based Delivery → Drug Delivery Systems
Administration
Topical
01

Overview

A **hemostatic matrix + bovine thrombin** is a combination topical hemostatic agent composed of a gelatin-based matrix (usually derived from bovine collagen) and bovine thrombin. The gelatin matrix provides a mechanical barrier and tamponade effect, swelling to conform to wound contours and promoting initial platelet activation at the bleeding site. When the bovine thrombin component is added, it enzymatically converts fibrinogen to fibrin at the wound site, accelerating stable clot formation and supporting hemostasis via the final common coagulation pathway. This combination is used as an adjunct to conventional surgical methods for the control of oozing or minor bleeding during surgery, generally when standard measures are ineffective or impractical. With approval for use in a range of surgical fields, its effectiveness is achieved both through physical (gelatin matrix) and enzymatic (thrombin) hemostatic mechanisms. The gelatin matrix is bioresorbable, typically absorbed within several weeks. While generally safe, risks include immunologic reactions, particularly with bovine thrombin (such as antibody development and possible coagulopathies), and rarely, complications like thromboembolism if the product is inadvertently introduced into blood vessels[1][2][3][4][5][8].

Other names
gelatin-bovine thrombin hemostatic matrixgelatin-thrombin matrixGTM
02

Targets

GP9 (Platelet glycoprotein ib-ix-v complex)F2R (Protease-activated receptor 1)PAR4 (Protease-activated receptor 4)

Beyond the preview

Go deeper on hemostatic matrix + bovine thrombin.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on hemostatic matrix + bovine thrombin.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call